Conversely, disruption of MLVs or removal of dCLNs reduces DC-mediated drainage and CD8+ T cell activation, leading to diminished therapeutic efficacy and decreased survival rates in GBM models 17. The gene discussed is CD8A; the disease is glioblastoma.